Free Trial

Curaleaf (OTCMKTS:CURLF) Issues Earnings Results, Beats Expectations By $0.01 EPS

Curaleaf logo with Medical background

Key Points

  • Curaleaf reported a quarterly earnings per share of ($0.06), exceeding analysts' expectations of ($0.07) by $0.01.
  • The company's current ratio is 1.41 and it has a debt-to-equity ratio of 1.08, indicating manageable debt levels relative to its equity.
  • Shares of Curaleaf opened at $1.79, with a 12-month low of $0.68 and a high of $3.58.
  • Want stock alerts on Curaleaf? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Curaleaf (OTCMKTS:CURLF - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01, Zacks reports. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.41%.

Curaleaf Stock Performance

Shares of CURLF stock opened at $1.79 on Friday. Curaleaf has a 12 month low of $0.68 and a 12 month high of $3.58. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.41 and a quick ratio of 0.70. The firm has a market capitalization of $1.20 billion, a P/E ratio of -5.59 and a beta of 0.69. The company's fifty day moving average price is $1.05 and its two-hundred day moving average price is $1.05.

Curaleaf Company Profile

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Recommended Stories

Earnings History for Curaleaf (OTCMKTS:CURLF)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines